ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers

Not Applicable

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: nicotine patch
Drug: varenicline

First Posted Date: 2013-01-18

Last Posted Date: 2020-09-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 300

Registration Number: NCT01771627

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Not Applicable

Withdrawn

Conditions: Stage II Renal Cell Cancer
Stage III Renal Cell Cancer

Interventions: Drug: tivozanib
Procedure: therapeutic conventional surgery

First Posted Date: 2013-01-17

Last Posted Date: 2022-08-15

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01769885

Breast and Cervical Cancer Educational Intervention for Latinas in Western New York

Not Applicable

Completed

Conditions: Breast Cancer
Cervical Cancer

Interventions: Other: educational intervention
Other: questionnaire administration

First Posted Date: 2013-01-04

Last Posted Date: 2022-10-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 959

Registration Number: NCT01760850

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery

Phase 2

Terminated

Conditions: Ductal Breast Carcinoma In Situ
Estrogen Receptor Negative
HER2/Neu Negative
Invasive Cribriform Breast Carcinoma
Papillary Breast Carcinoma
Progesterone Receptor Positive
Estrogen Receptor Positive
Stage II Breast Cancer
Stage IIIA Breast Cancer
Invasive Ductal Carcinoma, Not Otherwise Specified

Interventions: Procedure: Therapeutic Conventional Surgery
Radiation: Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment

First Posted Date: 2012-12-21

Last Posted Date: 2017-07-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01754519

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Broccoli Sprout Extract in Treating Patients With Breast Cancer

Early Phase 1

Completed

Conditions: Ductal Breast Carcinoma
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Ductal Breast Carcinoma In Situ
Estrogen Receptor Negative
Estrogen Receptor Positive
Invasive Breast Carcinoma
Lobular Breast Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Broccoli Sprout Extract
Other: Pharmacological Study
Other: Placebo

First Posted Date: 2012-12-20

Last Posted Date: 2019-10-31

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT01753908

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma

Phase 1

Terminated

Conditions: Stage IV Skin Melanoma
Stage IIIB Skin Melanoma
Stage IIIC Skin Melanoma
Recurrent Melanoma

Interventions: Biological: Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-12-06

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01744171

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Phase 1

Withdrawn

Conditions: Mucositis
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Verrucous Carcinoma of the Oral Cavity
Stage III Squamous Cell Carcinoma of the Hypopharynx

Interventions: Drug: entolimod
Radiation: intensity-modulated radiation therapy
Drug: cisplatin
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2012-11-19

Last Posted Date: 2013-12-11

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01728480

Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer

Not Applicable

Withdrawn

Conditions: Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Verrucous Carcinoma of the Oral Cavity
Stage II Verrucous Carcinoma of the Oral Cavity
Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage I Verrucous Carcinoma of the Oral Cavity
Tongue Cancer
Recurrent Squamous Cell Carcinoma of the Oropharynx
Stage I Squamous Cell Carcinoma of the Oropharynx
Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage II Squamous Cell Carcinoma of the Oropharynx

Interventions: Drug: photodynamic therapy
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Drug: temoporfin

First Posted Date: 2012-10-31

Last Posted Date: 2014-09-03

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01718223

Biomarkers in Post-Menopausal Women Receiving Flaxseed

Not Applicable

Completed

Conditions: No Evidence of Disease

Interventions: Other: Clinical Observation
Dietary Supplement: Flaxseed
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration

First Posted Date: 2012-10-02

Last Posted Date: 2022-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 258

Registration Number: NCT01698294

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Phase 1

Active, not recruiting

Conditions: Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Pazopanib Hydrochloride
Other: Pharmacological Study

First Posted Date: 2012-09-13

Last Posted Date: 2024-11-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 51

Registration Number: NCT01684397

Locations: 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Karamanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy